Download the report to find out about the French pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Windrose Consulting Group are pleased to welcome the latest members of our team into the London office

Download the report to find out how pricing and reimbursement decisions are made in the US, including, Payer Evaluation, Price setting and reimbursement

Download the report to find out how pricing and reimbursement decisions are made in Italy, including, Payer Evaluation, Price setting and reimbursement

Windrose Consulting Group are pleased to welcome the latest members of our team into the UK office; Inés Dieringer and Joana Guedes.

Download the report to find out how pricing and reimbursement decisions are made in the UK, including, Payer Evaluation, Price setting and reimbursement

Windrose are delighted to announce twelve promotions in our team.

Windrose Consulting Group are pleased to welcome the latest members of our team into the UK office; Jenny Marsh, Aashray Gupta, Jason King and Mar Casajuana.

Windrose Consulting Group are delighted to welcome the latest members of our team into the US office; Ari Levin, Katharine K Yang, Jack Minigutti, Simon Rickman, Michelle Wang, Jasmine Line and Daniel Shapiro.

In this Q&A, we are featuring our 2024 Summer Interns; Amol and Ushaan

With less than a year to go until the launch of the Joint Clinical Assessment (JCA) in January 2025, its successful implementation relies on the readiness of each EU market and their willingness to incorporate the JCA into current HTA processes.

The recent FDA approval of two groundbreaking gene therapies for sickle cell disease —Casgevy and Lyfgenia—marks a significant milestone in the field, offering life-changing treatments for patients suffering from this debilitating genetic disorder.

On January 5th, 2024, the FDA allowed Florida the ability to import prescription drugs from Canada on a provisional basis.

A new, non-contractual voluntary agreement has been implemented in the UK since the start of January 2024 and is set to run for 5 years, between the Department of Health and Social Care (DHSC)*, NHS England, and the Association of British Pharmaceutical Industry (ABPI).

Windrose are delighted to announce four promotions in our team.

Registration is now open for Developing a Successful Biopharmaceutical Pricing & Market Access Strategy, May - July 2024.

Today, we are celebrating 9 years of Windrose Consulting Group!

UK MHRA’s International Recognition Procedure (IRP) launch marks a key post-Brexit Health Technology Assessment (HTA) milestone, in an effort to speed up patient access to new medicines in the UK

Affordability challenges can hinder patient access to medicines in many countries, especially those with low income or limited public health coverage. Thus, pharmaceutical companies are increasingly interested in exploring patient-targeted affordability solutions to widen access in the out-of-pocket (OOP) sector.

In recent years, Denmark has shifted from its “added medical value” framework for evaluating new medicines and indication expansions in heath technology assessments (HTA) in favor of a quality-adjusted life year (QALY) approach, similar to that of NICE’s approach in the UK.